ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

2024 . Kiladjian, Jean-Jacques | Marin, Francisca Ferrer | Al-Ali, Haifa Kathrin | Alvarez-Larrán, Alberto | Beggiato, Eloise | Bieniaszewska, Maria | Breccia, Massimo | Buxhofer-Ausch, Veronika | Cerna, Olga | Crisan, Ana-Manuela | Danaila, Catalin Doru | De Stefano, Valerio | Döhner, Konstanze | Empson, Victoria | Gora-Tybor, Joanna | Griesshammer, Martin | Grosicki, Sebastian | Guglielmelli, Paola | García-Gutierrez, Valentin | Heidel, Florian H. | Illés, Arpád | Tomuleasa, Ciprian | James, Chloe | Koschmieder, Steffen | Krauth, Maria-Theresa | Krejcy, Kurt | Lazaroiu, Mihaela-Cornelia | Mayer, Jiri | Nagy, Zsolt György | Nicolini, Franck-Emmanuel | Palandri, Francesca | Pappa, Vassiliki | Reiter, Andreas Johannes | Sacha, Tomasz | Schlager, Stefanie | Schmidt, Stefan | Terpos, Evangelos | Unger, Martin | Wölfler, Albert | Cirici, Blanca Xicoy | Klade, Christoph